# Lecture 07: Cancer Pharmacology ## Unit 2.12: Pharmacology --- ## Learning Objectives By the end of this lecture, students will be able to: 1. Describe the principles of cancer chemotherapy 2. Explain cytotoxic chemotherapy drug classes 3. Describe targeted therapy agents 4. Explain immunotherapy mechanisms 5. Describe hormonal therapy in cancer 6. Explain supportive care in oncology --- ## Lecture Outline ### I. Principles of Cancer Chemotherapy Cancer chemotherapy employs cytotoxic and cytostatic agents to eliminate malignant cells or control tumor growth through various mechanisms that exploit the vulnerabilities of rapidly dividing cells. The fundamental goal of chemotherapy varies based on clinical context, ranging from curative intent in chemosensitive malignancies to palliative control of symptoms and disease progression in advanced cancers. Treatment timing relative to surgical intervention defines adjuvant therapy, administered after surgery to eliminate micrometastatic disease, and neoadjuvant therapy, given before surgery to shrink tumors and facilitate resection. Understanding these treatment goals guides appropriate regimen selection and helps set realistic patient expectations regarding outcomes and toxicity burdens. The cell cycle provides the conceptual framework for understanding how different chemotherapy agents exert their effects and why combination therapy proves superior to single-agent treatment. Cells progress through defined phases including G1 (preparation for DNA synthesis), S phase (DNA replication), G2 (preparation for mitosis), and M phase (cell division), with a G0 quiescent state representing cells temporarily or permanently withdrawn from active cycling. Cell cycle-specific agents like antimetabolites and mitotic inhibitors kill cells only during particular phases, while cell cycle-nonspecific agents including alkylating agents and anthracyclines damage cells regardless of their position in the cycle. The growth fraction, representing the proportion of tumor cells actively cycling, determines chemotherapy sensitivity, with high growth fraction tumors showing greater responsiveness to cytotoxic therapy. Combination chemotherapy principles guide the construction of effective regimens that maximize tumor cell killing while maintaining tolerable toxicity profiles. Combining agents with different mechanisms of action targets multiple cellular vulnerabilities simultaneously, reducing the likelihood that resistant clones will survive treatment. Selecting drugs with non-overlapping toxicities allows each agent to be administered at full effective doses rather than requiring dose reductions that might compromise efficacy. Synergistic combinations achieve killing greater than the sum of individual agents, as seen when cell cycle-specific agents follow cell cycle-nonspecific agents that recruit quiescent cells into active cycling. These principles explain why established regimens like CHOP for lymphoma and FOLFOX for colorectal cancer combine mechanistically distinct agents. The log kill hypothesis provides the mathematical foundation for understanding tumor response to chemotherapy and the rationale for multiple treatment cycles. Each chemotherapy cycle kills a constant fraction of tumor cells rather than a constant number, meaning a treatment achieving 99% kill reduces tumor burden by two logs regardless of starting size. This fractional killing necessitates multiple cycles to progressively reduce tumor burden below the threshold for clinical detection and ultimate cure. Gompertzian growth kinetics describe how tumor growth rate slows as tumors enlarge due to nutrient limitations and cell cycle arrest, making smaller tumors with higher growth fractions more chemosensitive. Adjuvant chemotherapy exploits this principle by treating presumed micrometastatic disease when tumor burden is minimal and growth fraction maximal. Panel A: Treatment intent categories showing curative for testicular cancer and lymphoma, adjuvant for breast cancer post-surgery, neoadjuvant for locally advanced rectal cancer, and palliative for metastatic disease with treatment goals and outcomes. Panel B: Detailed cell cycle diagram with G0, G1, S, G2, and M phases showing antimetabolites acting in S phase, vinca alkaloids and taxanes acting in M phase, and alkylating agents and anthracyclines as cell cycle-nonspecific agents. Panel C: Combination chemotherapy principles with drug icons representing different mechanisms, Venn diagram of non-overlapping toxicity profiles, and synergy curves demonstrating enhanced killing with combinations. Panel D: Log kill hypothesis showing semi-logarithmic graph of tumor cell number declining in log increments with each treatment cycle, clinical detection threshold, and cure achieved through successive tumor burden reductions. --- ### II. Alkylating Agents Alkylating agents represent one of the oldest and most broadly used classes of cytotoxic chemotherapy, exerting their effects through covalent modification of DNA that interferes with replication and transcription. The mechanism involves transfer of alkyl groups to nucleophilic sites on DNA bases, particularly the N7 position of guanine, creating adducts that distort DNA structure and trigger cell death pathways. Bifunctional alkylating agents can cross-link DNA strands, creating lesions that are particularly difficult for cellular repair machinery to resolve. These agents act independently of cell cycle phase, damaging both dividing and quiescent cells, though actively replicating cells attempting to traverse damaged DNA templates suffer the most severe consequences. Nitrogen mustards, derived from chemical warfare agents developed during World War I, include several clinically important drugs with distinct spectra of activity and toxicity profiles. Cyclophosphamide requires hepatic activation to its active metabolites and demonstrates broad utility across hematologic malignancies, breast cancer, and as a component of conditioning regimens for stem cell transplantation. Ifosfamide, structurally similar to cyclophosphamide, produces higher levels of the acrolein metabolite responsible for hemorrhagic cystitis, necessitating co-administration of the protective agent mesna which binds acrolein in the urinary tract. Melphalan finds particular use in multiple myeloma treatment, while chlorambucil serves as an oral option for chronic lymphocytic leukemia in patients unable to tolerate more intensive regimens. Platinum compounds represent a distinct subclass of alkylating-like agents that form intrastrand and interstrand DNA cross-links through coordination chemistry rather than true alkylation. Cisplatin, the prototype agent, demonstrates particular efficacy in testicular cancer, achieving cure rates exceeding 90% in combination regimens, and plays central roles in lung, ovarian, bladder, and head and neck cancer treatment. The drug causes severe nausea requiring aggressive antiemetic prophylaxis, nephrotoxicity necessitating vigorous hydration and renal function monitoring, ototoxicity with high-frequency hearing loss, and peripheral neuropathy. Carboplatin provides similar antitumor activity with substantially reduced nephrotoxicity, ototoxicity, and nausea, though myelosuppression, particularly thrombocytopenia, becomes dose-limiting. Oxaliplatin uniquely contributes to colorectal cancer treatment and causes a distinctive cold-induced peripheral neuropathy. Alkylating agent toxicities extend beyond the acute effects to include concerning long-term consequences that influence treatment decisions and survivorship care. Myelosuppression affects all lineages with nadir counts typically occurring 10-14 days after treatment, requiring growth factor support and infection precautions in high-risk patients. Hemorrhagic cystitis from cyclophosphamide and ifosfamide results from acrolein accumulation in urine and is prevented by adequate hydration and mesna administration. Pulmonary fibrosis represents a concerning toxicity with busulfan and carmustine, requiring baseline and surveillance pulmonary function testing. Perhaps most significantly, alkylating agents carry the highest risk of treatment-related secondary malignancies, particularly myelodysplastic syndrome and acute myeloid leukemia developing 5-10 years after exposure. Panel A: Mechanism of DNA alkylation showing guanine N7 alkylation, monoadduct formation, and interstrand cross-linking preventing DNA strand separation with downstream consequences of replication block, transcription errors, and cell death. Panel B: Nitrogen mustard structures and metabolism showing cyclophosphamide hepatic activation to phosphoramide mustard plus acrolein with mesna protection, and comparative features of ifosfamide, melphalan, and chlorambucil with clinical uses. Panel C: Platinum compound mechanisms showing cisplatin, carboplatin, and oxaliplatin structures with DNA coordination chemistry forming intrastrand cross-links and comparison table of nephrotoxicity, ototoxicity, myelosuppression, and neuropathy. Panel D: Alkylating agent toxicities organized by timing showing acute nausea and myelosuppression with nadir graph, subacute hemorrhagic cystitis with prevention strategies, and delayed pulmonary fibrosis and secondary malignancies with monitoring recommendations. --- ### III. Antimetabolites Antimetabolites structurally resemble normal cellular metabolites and disrupt nucleic acid synthesis by incorporating into DNA or RNA or by inhibiting enzymes required for nucleotide production. These agents exert their greatest effects during S phase when cells actively replicate their genomes, making them cell cycle-specific with particular efficacy against rapidly proliferating tumors. The therapeutic index depends on differential susceptibility of malignant versus normal cells, with intestinal epithelium, bone marrow, and hair follicles representing the normal tissues most affected due to their high proliferative rates. Understanding the biochemical pathways targeted allows prediction of drug interactions, toxicities, and potential synergies in combination regimens. Antifolates inhibit enzymes in the folate pathway required for one-carbon transfers essential to purine and pyrimidine synthesis. Methotrexate inhibits dihydrofolate reductase, preventing regeneration of tetrahydrofolate from dihydrofolate and thereby depleting the reduced folate pool needed for thymidylate and purine synthesis. Clinical applications span acute lymphoblastic leukemia, osteosarcoma, choriocarcinoma, and autoimmune conditions at lower doses, with toxicity including mucositis, myelosuppression, hepatotoxicity, and renal injury from crystallization in acidic urine. High-dose methotrexate protocols require leucovorin rescue, providing reduced folate that bypasses the blocked enzyme and rescues normal tissues while maintaining antitumor effect in cells less efficient at folate uptake. Pemetrexed inhibits multiple folate-dependent enzymes and finds primary use in mesothelioma and non-squamous non-small cell lung cancer, requiring vitamin supplementation to reduce toxicity. Pyrimidine analogs interfere with DNA and RNA synthesis through various mechanisms targeting thymidylate production and DNA polymerase function. Fluorouracil, converted intracellularly to active metabolites, inhibits thymidylate synthase through formation of a ternary complex that irreversibly blocks enzyme function, depleting thymidine pools required for DNA synthesis. Clinical uses span colorectal cancer, breast cancer, and head and neck cancers, with toxicity depending on administration schedule and genetic polymorphisms in metabolizing enzymes like dihydropyrimidine dehydrogenase. Capecitabine serves as an oral prodrug converted to fluorouracil preferentially in tumor tissue through a three-step activation pathway exploiting higher tumor expression of converting enzymes. Cytarabine and gemcitabine incorporate into DNA and inhibit DNA polymerase, with cytarabine representing a cornerstone of acute myeloid leukemia treatment while gemcitabine contributes to pancreatic, lung, and bladder cancer regimens. Purine analogs disrupt DNA and RNA synthesis through incorporation into nucleic acids and inhibition of purine biosynthesis pathways. Mercaptopurine and thioguanine undergo intracellular activation to nucleotides that inhibit de novo purine synthesis and incorporate into DNA causing strand breaks and apoptosis. These agents require dose reduction in patients receiving allopurinol, which inhibits xanthine oxidase-mediated inactivation, and in patients with thiopurine methyltransferase deficiency who experience severe toxicity at standard doses. Fludarabine demonstrates particular efficacy against chronic lymphocytic leukemia and indolent lymphomas, causing profound immunosuppression through depletion of T lymphocytes that increases infection risk. Cladribine provides definitive treatment for hairy cell leukemia, often achieving durable remissions with a single course of therapy. Panel A: Folate pathway showing dihydrofolate reductase converting dihydrofolate to tetrahydrofolate blocked by methotrexate, tetrahydrofolate contributing to thymidylate synthase and purine synthesis, leucovorin rescue bypassing the block, and high-dose methotrexate protocol timeline. Panel B: Pyrimidine analog mechanisms showing fluorouracil forming ternary complex with thymidylate synthase and folate cofactor, capecitabine three-step activation in tumor tissue, and cytarabine and gemcitabine DNA polymerase inhibition and incorporation. Panel C: Purine analog pathways showing mercaptopurine and thioguanine activation, incorporation into DNA, and TPMT pharmacogenetic consideration with dose modification recommendations based on enzyme activity. Panel D: Clinical applications matrix with antimetabolites and cancer types showing S-phase specificity, typical toxicities including mucositis, myelosuppression, and hand-foot syndrome, and key drug interactions. --- ### IV. Antitumor Antibiotics and Topoisomerase Inhibitors Anthracyclines rank among the most effective and widely used antineoplastic agents, contributing to curative regimens for breast cancer, lymphomas, sarcomas, and acute leukemias. The mechanism involves multiple effects including DNA intercalation that unwinds the double helix, inhibition of topoisomerase II leading to DNA strand breaks, and generation of free radicals through iron-dependent reactions. Doxorubicin serves as the prototype, with daunorubicin used primarily in leukemia, epirubicin as a less cardiotoxic alternative for breast cancer, and idarubicin offering improved oral bioavailability for leukemia treatment. The characteristic red color of anthracyclines causes harmless red discoloration of urine that should be explained to patients. Anthracycline cardiotoxicity represents the most concerning long-term adverse effect, manifesting as dose-dependent cardiomyopathy that may be irreversible. The mechanism involves free radical generation and iron accumulation in cardiac myocytes, which lack the enzymatic defenses to neutralize oxidative stress present in other tissues. Cumulative dose limits guide treatment decisions, with doxorubicin doses exceeding 450-550 mg/m2 carrying substantially increased heart failure risk, though some patients develop toxicity at lower exposures. Dexrazoxane, an iron chelator, provides cardioprotection when administered before anthracycline infusion but concerns about reducing antitumor efficacy have limited its use to patients receiving high cumulative doses. Baseline echocardiography and serial monitoring during treatment allow early detection of declining ejection fraction that may prompt treatment modification. Bleomycin, mitomycin C, and dactinomycin represent non-anthracycline antitumor antibiotics with distinct mechanisms and clinical applications. Bleomycin causes DNA strand breaks through an iron and oxygen-dependent mechanism, finding use in testicular cancer, Hodgkin lymphoma, and squamous cell carcinomas, with pulmonary fibrosis as the dose-limiting toxicity requiring careful cumulative dose monitoring. The drug lacks myelosuppressive effects, making it valuable in combination with myelotoxic agents. Mitomycin C functions as an alkylating agent after intracellular reduction and contributes to gastrointestinal and bladder cancer treatment. Dactinomycin binds DNA and inhibits RNA synthesis, playing crucial roles in Wilms tumor and gestational trophoblastic disease with potent myelosuppression and severe vesicant properties. Topoisomerase inhibitors trap enzyme-DNA complexes, converting normally transient strand breaks into permanent lesions that trigger cell death. Topoisomerase I inhibitors irinotecan and topotecan stabilize the cleavable complex of topoisomerase I with DNA, causing S-phase specific killing through replication fork collision with the trapped enzyme. Irinotecan undergoes hepatic conversion to the active metabolite SN-38 and contributes significantly to colorectal cancer treatment, with early-onset cholinergic diarrhea and delayed severe diarrhea representing characteristic toxicities. Topoisomerase II inhibitors etoposide and teniposide stabilize the analogous complex with topoisomerase II, causing double-strand breaks that are more difficult to repair. These agents contribute to small cell lung cancer, testicular cancer, and lymphoma treatment, with a distinctive risk of therapy-related acute myeloid leukemia typically presenting within 2-3 years after treatment. Panel A: Anthracycline mechanisms showing DNA double helix with intercalation, topoisomerase II trapped on DNA with strand breaks, and free radical generation through iron-dependent redox cycling, with doxorubicin, daunorubicin, epirubicin, and idarubicin primary uses. Panel B: Anthracycline cardiotoxicity showing heart cross-section with cardiac myocytes, iron accumulation and oxidative stress damage, cumulative dose-response curve for heart failure risk, echocardiogram monitoring timeline, and dexrazoxane protection mechanism. Panel C: Bleomycin pulmonary toxicity showing lung tissue with fibroblast activation and collagen deposition, cumulative dose limits, and pulmonary function monitoring schedule, alongside mitomycin and dactinomycin clinical applications. Panel D: Topoisomerase I and II inhibitor mechanisms showing topoisomerase I creating single-strand nick with irinotecan and topotecan trapping, and topoisomerase II creating double-strand break with etoposide and teniposide trapping, plus SN-38 metabolism and secondary leukemia risk. --- ### V. Mitotic Inhibitors Mitotic inhibitors target the microtubule network essential for chromosome segregation during cell division, causing mitotic arrest and subsequent cell death through apoptosis. Microtubules are dynamic structures composed of alpha and beta tubulin heterodimers that undergo continuous polymerization at plus ends and depolymerization at minus ends, with this dynamic instability essential for the chromosome movements of mitosis. Drugs interfering with microtubule dynamics arrest cells in M phase when the mitotic checkpoint detects abnormal spindle structure and prevents progression to anaphase. Prolonged mitotic arrest eventually triggers apoptosis through accumulation of pro-apoptotic signals and degradation of survival factors. Vinca alkaloids, derived from the periwinkle plant, bind to tubulin dimers and prevent microtubule assembly, causing dissolution of the mitotic spindle and cell death. Vincristine demonstrates broad utility in acute lymphoblastic leukemia and lymphoma treatment, with peripheral neuropathy as its dose-limiting toxicity causing sensory, motor, and autonomic dysfunction. The drug causes minimal myelosuppression, allowing combination with myelotoxic agents at full doses. Vinblastine contributes to Hodgkin lymphoma and testicular cancer regimens, with more prominent myelosuppression but less neurotoxicity than vincristine. Vinorelbine provides activity in lung and breast cancer with an intermediate toxicity profile. All vinca alkaloids are severe vesicants requiring careful administration through secure intravenous access. Taxanes stabilize microtubules in a mechanism opposite to vinca alkaloids, preventing the depolymerization necessary for normal microtubule dynamics and chromosome movement. Paclitaxel, originally derived from Pacific yew tree bark, demonstrates remarkable activity in ovarian, breast, and lung cancers and has become one of the most widely used anticancer agents. The drug requires solubilization in Cremophor EL, a castor oil derivative that causes hypersensitivity reactions necessitating premedication with corticosteroids, antihistamines, and H2 blockers. Docetaxel, a semisynthetic derivative formulated in polysorbate 80, finds use in similar malignancies with fluid retention as a distinctive toxicity requiring corticosteroid prophylaxis. Both agents cause myelosuppression and dose-dependent peripheral neuropathy that may limit cumulative dosing. Peripheral neuropathy represents the most significant non-hematologic toxicity of microtubule-targeting agents, often persisting after treatment completion and significantly impacting quality of life. The mechanism involves disruption of axonal transport dependent on microtubule function, leading to dying-back degeneration of long sensory fibers first. Symptoms begin with numbness and paresthesias in fingers and toes, progressing to loss of proprioception and fine motor coordination that may impair activities of daily living. Vincristine causes a more prominent motor component with foot drop and weakness, while taxanes produce primarily sensory neuropathy. Dose modifications and treatment discontinuation may be necessary to prevent irreversible neurologic damage, and no proven preventive or therapeutic interventions exist despite extensive investigation. Panel A: Microtubule structure and dynamics showing alpha-beta tubulin heterodimers, plus and minus end dynamics, mitotic spindle attaching to chromosomes at kinetochores, and mitotic checkpoint activation when spindle function is disrupted. Panel B: Vinca alkaloid mechanism showing drug binding to tubulin dimers preventing polymerization, spindle dissolution, and comparison of vincristine neuropathy, vinblastine myelosuppression, and vinorelbine toxicity profiles with vesicant warning. Panel C: Taxane mechanism showing drug binding to assembled microtubules preventing depolymerization, frozen spindle unable to separate chromosomes, hypersensitivity reaction management with premedication protocols, and docetaxel fluid retention prophylaxis. Panel D: Peripheral neuropathy pathophysiology showing nerve fiber with axonal transport disruption, dying-back degeneration pattern, NCI-CTCAE clinical assessment grading, and dose modification guidelines based on symptom severity. --- ### VI. Targeted Therapy Targeted therapies exploit specific molecular alterations in cancer cells, providing enhanced selectivity compared to cytotoxic chemotherapy and often improved tolerability despite their own characteristic toxicity profiles. The development of targeted agents requires identification of oncogenic driver mutations or pathway activations upon which tumors depend for survival and proliferation. Companion diagnostic testing determines which patients harbor the molecular targets and will benefit from specific targeted agents, representing a paradigm of precision oncology. Unlike cytotoxic agents that affect all rapidly dividing cells, targeted therapies may achieve durable responses by blocking the specific molecular dependencies of individual tumors. Tyrosine kinase inhibitors represent small molecules that penetrate cells and inhibit intracellular signaling enzymes by competing with ATP at the kinase active site. Imatinib revolutionized chronic myeloid leukemia treatment by targeting the BCR-ABL fusion protein created by the Philadelphia chromosome, converting a previously fatal disease into a manageable chronic condition with oral medication. The drug also inhibits c-KIT, providing dramatic efficacy in gastrointestinal stromal tumors that previously had no effective systemic therapy. Resistance develops through kinase domain mutations that prevent imatinib binding, prompting development of second and third-generation inhibitors like dasatinib and ponatinib that retain activity against common resistance mutations. Epidermal growth factor receptor inhibitors including erlotinib and osimertinib benefit non-small cell lung cancer patients with activating EGFR mutations, while BRAF inhibitors like vemurafenib target melanomas with BRAF V600E mutations. Monoclonal antibodies target cell surface receptors and extracellular proteins, blocking ligand binding, inducing receptor internalization, or recruiting immune effector mechanisms for cell killing. Trastuzumab binds the HER2 receptor overexpressed in approximately 20% of breast cancers, blocking signaling and inducing antibody-dependent cellular cytotoxicity, transforming prognosis for this aggressive subtype. Rituximab targets CD20 on B lymphocytes, providing activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia through multiple mechanisms including complement activation and direct apoptosis induction. Bevacizumab binds vascular endothelial growth factor, blocking tumor angiogenesis and contributing to treatment of colorectal, lung, and other cancers, with hypertension, proteinuria, and bleeding as characteristic toxicities. Cetuximab and panitumumab target EGFR in colorectal cancer, though benefit is limited to tumors with wild-type KRAS and other RAS pathway genes. CDK4/6 inhibitors and PARP inhibitors represent newer targeted therapy classes with transformative impact on specific cancer populations. Palbociclib, ribociclib, and abemaciclib inhibit cyclin-dependent kinases 4 and 6 that drive G1 to S phase transition, providing benefit in hormone receptor-positive breast cancer when combined with endocrine therapy. Neutropenia represents the primary toxicity requiring dose adjustment and monitoring. PARP inhibitors including olaparib, niraparib, and rucaparib exploit synthetic lethality in tumors with homologous recombination deficiency, particularly those with BRCA1 or BRCA2 mutations. Blocking poly-ADP-ribose polymerase prevents single-strand break repair, causing replication fork collapse and cell death in cells unable to perform error-free double-strand break repair through the homologous recombination pathway. Panel A: Tyrosine kinase inhibitor mechanisms showing BCR-ABL fusion protein structure, imatinib binding to ATP-binding pocket, resistance mutations in kinase domain, and evolution to second and third generation inhibitors dasatinib and ponatinib with mutation coverage. Panel B: Monoclonal antibody mechanisms showing cell surface receptor binding with trastuzumab-HER2 and rituximab-CD20, ligand trapping with bevacizumab-VEGF, and downstream effects including signal blockade, internalization, and immune effector recruitment. Panel C: CDK4/6 inhibitor mechanism showing G1/S checkpoint control, cyclin D-CDK4/6 phosphorylating Rb protein, drug inhibition maintaining Rb in active tumor suppressor state, and combination with endocrine therapy in HR-positive breast cancer. Panel D: PARP inhibitor mechanism and synthetic lethality showing PARP enzyme repairing single-strand breaks, PARP inhibition causing replication fork collapse, BRCA-deficient cells unable to repair through homologous recombination, and BRCA-proficient cells surviving through intact HR pathway. --- ### VII. Immunotherapy Cancer immunotherapy harnesses the immune system to recognize and eliminate tumor cells, representing a paradigm shift from directly cytotoxic approaches to manipulation of host defense mechanisms. Tumors evade immune destruction through multiple mechanisms including downregulation of antigen presentation, expression of immunosuppressive ligands, recruitment of regulatory cells, and secretion of immunosuppressive cytokines. Immunotherapy agents reverse these evasion mechanisms, reinvigorating antitumor immunity that can achieve durable responses even after treatment discontinuation. The concept that tumors can be controlled by immune surveillance dates to early observations of spontaneous remissions and responses to infections, but effective therapeutic application required understanding of immune checkpoint pathways. Immune checkpoint inhibitors block inhibitory receptors that normally terminate immune responses, releasing the brakes on antitumor T cell activity. Programmed death-1 and its ligand PD-L1 represent the most clinically significant checkpoint pathway, with pembrolizumab and nivolumab blocking PD-1 while atezolizumab and durvalumab block PD-L1. These agents demonstrate activity across numerous malignancies including melanoma, lung cancer, renal cell carcinoma, bladder cancer, and Hodgkin lymphoma, with PD-L1 expression and tumor mutational burden serving as imperfect predictive biomarkers. CTLA-4 inhibition by ipilimumab blocks an earlier checkpoint operating in lymph nodes during T cell priming, with combination of CTLA-4 and PD-1 blockade providing enhanced efficacy at the cost of increased toxicity in melanoma and other cancers. Immune-related adverse events distinguish checkpoint inhibitor toxicity from conventional chemotherapy, reflecting the inflammatory consequences of unleashing autoimmune potential. Dermatologic manifestations include rash and vitiligo, the latter associated with favorable outcomes in melanoma suggesting shared antigens between tumor and melanocytes. Colitis presents with diarrhea and abdominal pain, requiring colonoscopy for diagnosis and corticosteroids for treatment, with infliximab reserved for refractory cases. Endocrine toxicities include thyroiditis progressing through hyperthyroid to hypothyroid phases, hypophysitis causing panhypopituitarism, and type 1 diabetes from autoimmune beta cell destruction. Hepatitis and pneumonitis can be life-threatening, requiring prompt recognition and aggressive immunosuppression, with treatment held for significant toxicity and sometimes permanently discontinued. Chimeric antigen receptor T cell therapy represents the most sophisticated form of cancer immunotherapy, engineering patient T cells to express synthetic receptors targeting tumor antigens. CAR constructs combine an extracellular antibody-derived binding domain with intracellular T cell signaling domains, creating receptors that recognize cell surface antigens independent of MHC presentation. Tisagenlecleucel and axicabtagene ciloleucel target CD19 for relapsed/refractory acute lymphoblastic leukemia and diffuse large B cell lymphoma, achieving remarkable response rates in heavily pretreated patients. Cytokine release syndrome results from massive T cell activation and cytokine production, causing fever, hypotension, and hypoxia that may require intensive care support and treatment with the IL-6 receptor antagonist tocilizumab. Neurotoxicity manifesting as encephalopathy, seizures, and cerebral edema represents another serious complication requiring careful monitoring and supportive care. Panel A: Immune checkpoint mechanisms showing T cell engaging antigen-presenting cell, PD-1/PD-L1 interaction inhibiting T cell activation, CTLA-4 competing with CD28 for B7 binding, and checkpoint inhibitor antibodies blocking these inhibitory interactions. Panel B: Immune-related adverse events by organ system showing skin rash and vitiligo, GI colitis, endocrine thyroiditis, hypophysitis, and diabetes, liver hepatitis, and lung pneumonitis with treatment algorithms for each. Panel C: CAR-T cell therapy process showing patient leukapheresis, T cell isolation, viral transduction with CAR construct, expansion, and reinfusion, with CAR structure showing scFv binding domain, hinge, transmembrane domain, and signaling domains. Panel D: CAR-T complications showing cytokine release syndrome timeline with fever, hypotension, and hypoxia requiring tocilizumab, and neurotoxicity spectrum from confusion to seizures to cerebral edema with grading and management. --- ### VIII. Hormonal Therapy Hormonal therapies exploit the hormone dependence of certain malignancies, particularly breast and prostate cancers that express steroid hormone receptors and require hormonal signaling for growth and survival. The fundamental strategy involves either blocking hormone receptors to prevent signaling or eliminating hormone production through surgical or chemical ablation. These approaches provide efficacy with generally favorable tolerability compared to cytotoxic chemotherapy, making them suitable for prolonged administration in both adjuvant and metastatic settings. Hormone receptor status determined by immunohistochemistry guides treatment selection and predicts likelihood of benefit from endocrine therapy. Breast cancer hormonal therapies target the estrogen receptor pathway through receptor antagonism, receptor degradation, or elimination of estrogen production. Tamoxifen functions as a selective estrogen receptor modulator, acting as an antagonist in breast tissue while exerting agonist effects in bone (preventing osteoporosis) and endometrium (increasing endometrial cancer risk). The drug provides substantial benefit in both premenopausal and postmenopausal patients, reducing recurrence and mortality in adjuvant settings and providing disease control in metastatic disease. Aromatase inhibitors including anastrozole, letrozole, and exemestane block the aromatase enzyme that converts androgens to estrogens in peripheral tissues, eliminating estrogen production in postmenopausal women. These agents demonstrate superior efficacy to tamoxifen in postmenopausal patients but cause bone loss, arthralgias, and musculoskeletal symptoms requiring careful monitoring. Fulvestrant functions as a selective estrogen receptor degrader, binding the receptor and promoting its proteasomal degradation, eliminating both agonist and antagonist effects seen with SERMs. The drug requires intramuscular administration but provides a pure anti-estrogen effect useful when patients progress on other endocrine agents. CDK4/6 inhibitors combined with aromatase inhibitors or fulvestrant have become standard first-line treatment for metastatic hormone receptor-positive breast cancer, dramatically improving progression-free survival through synergistic blockade of proliferative signaling. Ovarian suppression using GnRH agonists or oophorectomy extends aromatase inhibitor use to premenopausal women and adds benefit to tamoxifen in high-risk patients. Prostate cancer hormonal therapy targets the androgen receptor pathway essential for prostate cancer cell survival and proliferation. Androgen deprivation therapy using GnRH agonists like leuprolide initially causes testosterone surge before suppressing production through pituitary downregulation, necessitating androgen receptor blockade during the flare period. GnRH antagonists like degarelix achieve immediate testosterone suppression without flare. Antiandrogens including bicalutamide block the androgen receptor but allow continued testosterone signaling at high levels. Novel antiandrogens enzalutamide and apalutamide provide more complete receptor blockade and nuclear translocation inhibition, demonstrating efficacy in castration-resistant prostate cancer. Abiraterone inhibits CYP17A1, blocking androgen synthesis in adrenal glands and tumor cells, providing additional benefit when combined with prednisone to prevent mineralocorticoid excess. Panel A: Breast cancer hormonal therapy mechanisms showing estrogen receptor structure, tamoxifen binding as competitive antagonist with agonist effects in bone and endometrium, aromatase inhibitor blocking peripheral estrogen synthesis, and fulvestrant causing receptor degradation. Panel B: Clinical algorithm for hormone receptor-positive breast cancer showing premenopausal versus postmenopausal pathways, first-line combination with CDK4/6 inhibitors, and sequential therapy options at progression. Panel C: Prostate cancer hormonal axis showing hypothalamus-pituitary-testis-adrenal pathways, GnRH agonist and antagonist effects on pituitary, antiandrogen receptor blockade, and CYP17A1 inhibition with drugs targeting each level. Panel D: Hormonal therapy toxicity profiles showing menopausal symptoms, bone effects including osteoporosis with monitoring strategy, metabolic effects of diabetes and cardiovascular risk with ADT, and thromboembolic risk with tamoxifen and management recommendations. --- ### IX. Supportive Care Supportive care measures prevent and manage the toxicities of cancer treatment, enabling patients to receive optimal therapy and maintain quality of life throughout their cancer journey. The recognition that adequate supportive care improves tolerance of treatment, reduces hospitalizations, and may enhance outcomes has elevated supportive oncology to a central position in cancer care. Multidisciplinary teams including oncologists, oncology nurses, pharmacists, nutritionists, social workers, and palliative care specialists coordinate comprehensive support addressing physical, emotional, and practical needs. Evidence-based guidelines provide frameworks for prevention and management of common treatment complications. Chemotherapy-induced nausea and vomiting remains one of patients' most feared toxicities despite dramatic improvements in prevention with modern antiemetic regimens. Emetogenic potential varies by agent, with cisplatin, anthracyclines, and cyclophosphamide at higher doses carrying the highest risk, determining the intensity of prophylactic regimens. High emetogenic risk chemotherapy requires three-drug prophylaxis with a 5-HT3 receptor antagonist such as ondansetron, the NK1 receptor antagonist aprepitant or fosaprepitant, and dexamethasone administered before chemotherapy and continued for several days after. The atypical antipsychotic olanzapine has emerged as an effective addition to standard regimens, particularly for delayed nausea and in patients at high risk for breakthrough symptoms. Breakthrough nausea requires additional agents with different mechanisms, including dopamine antagonists, benzodiazepines, or cannabinoids. Colony-stimulating factors prevent and treat chemotherapy-induced neutropenia, reducing infection risk and enabling dose-dense treatment schedules. Granulocyte colony-stimulating factor preparations including filgrastim and its pegylated long-acting form pegfilgrastim stimulate neutrophil production and accelerate recovery from chemotherapy-induced nadirs. Prophylactic use is indicated when regimen-associated febrile neutropenia risk exceeds 20% or when patient-specific factors increase risk with lower-risk regimens. Administration timing positions the growth factor to stimulate recovery without stimulating proliferation of progenitor cells during chemotherapy exposure, typically beginning 24-72 hours after chemotherapy completion. Erythropoiesis-stimulating agents find limited current use due to concerns about tumor progression and thromboembolic events, with transfusion preferred for symptomatic anemia. Other supportive measures address the diverse complications encountered during cancer treatment. Mucositis prevention includes cryotherapy for selected regimens and palifermin for high-dose chemotherapy with stem cell transplant, with pain management and nutritional support essential for established mucositis. Diarrhea management ranges from loperamide for mild symptoms to octreotide for severe cases, with particular attention to irinotecan-associated late diarrhea requiring aggressive intervention. Tumor lysis syndrome prevention with hydration, allopurinol or febuxostat, and in high-risk cases rasburicase protects against the metabolic complications of rapid tumor cell death. Bone-directed therapy with bisphosphonates or denosumab reduces skeletal events in patients with bone metastases while requiring monitoring for osteonecrosis of the jaw and atypical fractures. Panel A: Antiemetic regimen selection algorithm based on emetogenic risk showing highly emetogenic with 5-HT3 plus NK1 plus dexamethasone, moderately emetogenic with 5-HT3 plus dexamethasone, and low emetogenic with single agent PRN, plus receptor targets and breakthrough management. Panel B: G-CSF administration showing bone marrow with neutrophil precursor stimulation, timing diagram relative to chemotherapy with optimal administration window, absolute neutrophil count recovery curves with and without G-CSF support, and indications based on febrile neutropenia risk. Panel C: Tumor lysis syndrome pathophysiology showing tumor cell death releasing potassium, phosphorus, and nucleic acids metabolized to uric acid, with prevention strategies of hydration, allopurinol pathway, and rasburicase converting uric acid to allantoin. Panel D: Bone-directed therapy mechanisms showing osteoclast inhibition by bisphosphonates incorporated into bone matrix and denosumab RANKL antibody, skeletal event reduction, and complications of osteonecrosis of jaw and atypical fractures with prevention. --- ### X. Chemotherapy Toxicities Myelosuppression represents the most common dose-limiting toxicity of cytotoxic chemotherapy, affecting all hematopoietic lineages with varying severity and timing depending on the specific agents administered. Neutropenia creates risk for serious bacterial and fungal infections, with absolute neutrophil counts below 500 cells per microliter considered high risk for fever and infection requiring prompt evaluation and empiric antibiotic therapy. Nadir counts typically occur 10-14 days after chemotherapy administration, with recovery by days 21-28 allowing cycle repetition. Thrombocytopenia increases bleeding risk, with platelet transfusion indicated for counts below 10,000 per microliter or for higher thresholds with active bleeding or invasive procedures. Anemia develops more gradually due to the longer lifespan of red blood cells, causing fatigue that significantly impacts quality of life. Organ-specific toxicities require recognition, monitoring, and management to prevent permanent damage while maximizing treatment delivery. Doxorubicin cardiotoxicity mandates baseline echocardiography and serial monitoring, with treatment modification for declining ejection fraction and cumulative dose limits to prevent irreversible cardiomyopathy. Bleomycin pulmonary fibrosis risk increases with cumulative dose, concurrent radiation, and supplemental oxygen exposure, requiring pulmonary function monitoring and prompt evaluation of respiratory symptoms. Cisplatin nephrotoxicity prevention includes aggressive hydration to maintain high urine output and avoidance of concurrent nephrotoxic agents. Cyclophosphamide and ifosfamide require mesna to prevent hemorrhagic cystitis from acrolein accumulation. Neurotoxicity from vincristine, taxanes, and platinum agents may be irreversible, requiring dose modification at early signs of neuropathy. Extravasation of vesicant chemotherapy agents causes severe tissue injury requiring immediate intervention and potentially surgical debridement. Vesicants include anthracyclines, vinca alkaloids, and nitrogen mustards, which should be administered through central venous catheters when available. Recognition requires awareness that extravasation may present subtly with only mild pain or swelling initially, progressing over days to ulceration and necrosis. Dexrazoxane administered intravenously within 6 hours of anthracycline extravasation reduces tissue injury and need for surgery. Vinca alkaloid extravasation management includes warm compresses and hyaluronidase injection to disperse the drug and limit local concentration. Prevention through careful catheter placement verification, frequent monitoring during infusion, and patient education regarding symptoms remains paramount. Secondary malignancies represent a concerning late effect of cancer treatment, particularly with alkylating agents and topoisomerase II inhibitors. Alkylating agent-associated myelodysplastic syndrome and acute myeloid leukemia typically develop 5-10 years after exposure, often with complex cytogenetics and poor prognosis. Topoisomerase II inhibitor-related leukemias arise more rapidly, often within 2-3 years, with characteristic balanced translocations involving chromosome 11q23. Radiation therapy increases risk of solid tumors in irradiated fields, with latency periods of 10-20 years. This risk must be balanced against the immediate benefit of cancer treatment, with curative intent providing clear justification despite long-term risks, while palliative treatment decisions may weigh these considerations differently. Survivorship care includes education about signs and symptoms of secondary malignancies. Panel A: Myelosuppression showing bone marrow diagram with neutropenia ANC graph and nadir with fever management, thrombocytopenia with platelet count thresholds for transfusion and bleeding manifestations, and anemia with hemoglobin decline and fatigue impact with recovery timelines. Panel B: Organ-specific toxicities on body diagram showing heart with anthracycline monitoring protocol, lungs with bleomycin PFT decline, kidneys with cisplatin creatinine trends, bladder with cyclophosphamide and ifosfamide mesna timing, and peripheral nerves with neuropathy grading scale. Panel C: Extravasation recognition and management showing vesicant infusion with early signs of redness and swelling, progression to ulceration and necrosis, antidote administration with dexrazoxane for anthracyclines and hyaluronidase for vincas, and prevention with central line placement. Panel D: Secondary malignancy risk by drug class showing alkylating agents with MDS/AML at 5-10 years with complex cytogenetics, topoisomerase II inhibitors with AML at 2-3 years with 11q23 translocations, and radiation with solid tumors at 10-20 years with survivorship surveillance. --- ## Summary - Chemotherapy goals include curative, adjuvant, neoadjuvant, and palliative intent, with combination therapy using agents with different mechanisms and non-overlapping toxicities - Alkylating agents (cyclophosphamide, platinum compounds) cross-link DNA causing cell death, with myelosuppression, secondary malignancy risk, and organ-specific toxicities - Antimetabolites (methotrexate, fluorouracil, cytarabine) are S-phase specific agents mimicking normal substrates to disrupt nucleic acid synthesis - Anthracyclines (doxorubicin) intercalate DNA and inhibit topoisomerase II, causing cardiotoxicity requiring cumulative dose monitoring - Mitotic inhibitors include vincas (prevent microtubule assembly) and taxanes (prevent disassembly), with peripheral neuropathy as common toxicity - Targeted therapies include tyrosine kinase inhibitors (imatinib), monoclonal antibodies (trastuzumab, rituximab), CDK4/6 inhibitors, and PARP inhibitors - Checkpoint inhibitors (pembrolizumab, nivolumab, ipilimumab) release immune brakes; immune-related adverse events require steroids and checkpoint-specific management - CAR-T cell therapy engineers patient T cells to target CD19; cytokine release syndrome and neurotoxicity require specialized management - Hormonal therapy for breast cancer (tamoxifen, aromatase inhibitors) and prostate cancer (GnRH agonists, enzalutamide, abiraterone) targets hormone-dependent growth - Supportive care includes antiemetics (5-HT3/NK1 antagonists), G-CSF for neutropenia, and prevention of tumor lysis syndrome --- ## Key Terms | Term | Definition | |------|------------| | Adjuvant | Chemotherapy administered after definitive surgery to eliminate micrometastatic disease | | Neoadjuvant | Chemotherapy given before surgery to shrink tumors and facilitate resection | | Myelosuppression | Bone marrow toxicity causing decreased blood cell production and cytopenias | | Targeted therapy | Drug designed to attack specific molecular alterations in cancer cells | | Checkpoint inhibitor | Antibody blocking immune inhibitory receptors to release T cell antitumor activity | | irAE | Immune-related adverse event; autoimmune toxicity from checkpoint inhibition | | CAR-T | Chimeric antigen receptor T cells; engineered T cells expressing synthetic tumor-targeting receptors | | Vesicant | Chemotherapy agent causing severe tissue necrosis if extravasated | --- *This content is subject to the [MIT License](https://opensource.org/licenses/MIT). © 2024–2026 Hibbert School of Medicine.*